Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 5/20 | 0.57 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.57 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.54 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.53 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | LAP3 | P28838 | 2/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.45 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.45 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27084627 | 1.00 | SLC1A2 (0.57) | SLC1A2SLC1A3GABRR1SLC1A1CPA1 | |
| SCHEMBL5592479 | 0.82 | SLC1A3 (0.59) | SLC1A2SLC1A3GABRR1SLC1A1SLC7A5 | |
| SCHEMBL31544400 | 0.81 | SLC1A2 (0.56) | SLC1A2SLC1A3SLC1A1CPA1SLC7A5 | |
| SCHEMBL1058202 | 0.81 | SLC1A3 (0.61) | SLC1A2SLC1A3GABRR1SLC1A1CPA1 | |
| SCHEMBL4738612 | 0.81 | SLC1A3 (0.61) | SLC1A2SLC1A3GABRR1SLC1A1CPA1 | |
| SCHEMBL29950790 | 0.81 | SLC1A3 (0.61) | SLC1A2SLC1A3GABRR1SLC1A1CPA1 | |
| SCHEMBL1371975 | 0.80 | GABRR1 (0.55) | SLC1A2SLC1A3GABRR1SLC1A1GRIK1 | |
| SCHEMBL276879 | 0.80 | SLC1A3 (0.73) | SLC1A2SLC1A3SLC1A1CPA1SLC7A5 | |
| SCHEMBL20657164 | 0.79 | SLC1A3 (0.55) | SLC1A2SLC1A3GABRR1SLC1A1CPA1 | |
| SCHEMBL20657135 | 0.79 | SLC1A3 (0.55) | SLC1A2SLC1A3GABRR1SLC1A1CPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240423937-A1 | METHODS OF TREATING PAIN AND USES THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2024-12-26 | — | — | US | disclosed |
| US-20240156765-A1 | METHODS OF NEUROPROTECTION AND USES THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2024-05-16 | — | — | US | disclosed |
| US-20240041808-A1 | METHODS OF NEUROPROTECTION AND USES THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2024-02-08 | — | — | US | disclosed |
| CN-116322664-A | Method of neuroprotection and uses thereof | 欧库罗治疗有限责任公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2011086565-A1 | METHOD FOR PREPARATION OF ENANTIOMERICALLY ENRICHED AND/OR RACEMIC GAMMA-AMINO ACIDS | LUPIN LIMITED (IN) | 2011-07-21 | — | — | WO | disclosed |
| WO-2009127560-A1 | INTERMEDIATES FOR THE PREPARATION OF PREGABALIN AND PROCESS FOR THEIR PREPARATION | CHEMO IBÉRICA, S.A. (ES) | 2009-10-22 | — | — | WO | disclosed |
| WO-2008138874-A1 | PROCESS FOR PREPARING (S)-PREGABALIN BY OPTICAL RESOLUTION OF RACEMIC PREGABALIN | CHEMO IBÉRICA, S.A. (ES) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008117305-A2 | A NOVEL PROCESS FOR PREPARING PREGABALIN AND ITS ACID ADDITION SALTS | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2008-10-02 | — | — | WO | disclosed |
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | disclosed |
| CN-1310872-C | Mono- and disubstituted 3-propyl gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2007-04-18 | — | — | CN | disclosed |
| CN-1660779-A | Mono- and disubstituted 3-propyl gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2005-08-31 | — | — | CN | disclosed |
| CN-1196671-C | Mono-and disubstituted 3-propyl-gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2005-04-13 | — | — | CN | disclosed |
| CN-1355784-A | Mono-and disubstituted 3-propyl-gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2002-06-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041808-A1 | METHODS OF NEUROPROTECTION AND USES THEREOF | NLN, BDNF, GAP43 | SLC1A2 182/4885SLC1A3 279/4885GABRR1 81/4885 |
| US-20240423937-A1 | METHODS OF TREATING PAIN AND USES THEREOF | ACHE, PDE6G, PTGES3 | SLC1A2 779/4885SLC1A3 801/4885GABRR1 174/4885 |
| US-20240156765-A1 | METHODS OF NEUROPROTECTION AND USES THEREOF | NLN, BDNF, GAP43 | SLC1A2 182/4885SLC1A3 279/4885GABRR1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.